MedTrace Logo

Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

NCT01102712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2012-02-23

No results posted yet for this study

Summary

To establish and confirm the safety and clinical utility of BTVA applied unilaterally for lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.

Conditions

Interventions

DEVICE

BTVA System

Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction

Sponsors & Collaborators

  • Uptake Medical Corp

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-12-31
Completion
2011-08-31

Countries

  • Australia
  • Austria
  • Germany
  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102712 on ClinicalTrials.gov